Sorafenib Plus Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Versus Sorafenib Alone for Advanced Hepatocellular Carcinoma

Yang Zhao,JiaYing Lai,RunBin Liang,MinKe He,Ming Shi

DOI: https://doi.org/10.1016/j.jimed.2019.07.005

2019-01-01

Journal of Interventional Medicine

Abstract:Objective: To compare the efficacy of sorafenib plus hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin to that of sorafenib alone in patients with advanced hepatocellular carcinoma (HCC).Methods: This was a retrospective,single-center trial.Between April 3,2017 and July 2,2018,104 patients with Child-Pugh A and advanced HCC received either 400 mg of sorafenib orally twice daily plus HAIC with oxaliplatin (oxaliplatin 85 mg/m2,every 3 weeks via repetitive catheterization) (n =46,soraOXA group) or 400 mg of only sorafenib orally twice daily (n =58,sorafenib group).Overall survival,progression-free survival,objective response rate,and treatment-related adverse events were compared.Results: The median overall survival was 9.37 months (95％ CI,7.05-11.68) in the soraOXA group versus 4.8 months (95％ CI,2.98-6.62) in the sorafenib group (HR 0.46[95％ CI,0.29-0.72];P＜ 0.001).The soraOXA group also showed a higher objective response rate (16[34.8％]vs 1[1.7％];P ＜ 0.001) and a longer progressionfree survival rate (5.5 months[95％ CI,2.32-8.68]vs 2.4 months[95％ CI,1.65-3.15],HR 0.54[95％ CI,0.36-0.81],P=0.003) than the sorafenib group.There was no significant difference in the overall incidence of any grade adverse events,grade 3/4 adverse events,serious adverse events,or incidence of treatment termination due to adverse events between the two groups.Conclusion: Compared with sorafenib alone,sorafenib plus HAIC with oxaliplatin showed favorable treatment outcomes in patients with advanced HCC.The merits of this approach need to be established with a prospective trial.